Summary of Activity in Accrued Rebates and Chargebacks, Returns, Wholsesaler Service Fees and Prompt Pay Discounts |
for the years ended December 31, 2019, 2018 and 2017 (in thousands): | | | | | | | | | | | | | | | | | | | | | | Returns Allowances | | Prompt Payment Discounts | | Wholesaler Service Fees | | Volume Rebates and Chargebacks | | Total | Balance at December 31, 2016 | $ | 1,346 |
| | $ | 595 |
| | $ | 735 |
| | $ | 1,124 |
| | $ | 3,800 |
| Provision | 716 |
| | 5,806 |
| | 4,403 |
| | 4,656 |
| | 15,581 |
| Payments/Adjustments | (1,241 | ) | | (5,744 | ) | | (4,299 | ) | | (5,084 | ) | | (16,368 | ) | Balance at December 31, 2017 | 821 |
| | 657 |
| | 839 |
| | 696 |
| | 3,013 |
| Provision | 680 |
| | 6,802 |
| | 5,194 |
| | 6,645 |
| | 19,321 |
| Payments/Adjustments | (1,157 | ) | | (6,680 | ) | | (4,866 | ) | | (6,331 | ) | | (19,034 | ) | Balance at December 31, 2018 | 344 |
| | 779 |
| | 1,167 |
| | 1,010 |
| | 3,300 |
| Provision | 783 |
| | 8,426 |
| | 6,267 |
| | 11,475 |
| | 26,951 |
| Payments/Adjustments | (587 | ) | | (8,243 | ) | | (5,948 | ) | | (10,669 | ) | | (25,447 | ) | Balance at December 31, 2019 | $ | 540 |
| | $ | 962 |
| | $ | 1,486 |
| | $ | 1,816 |
| | $ | 4,804 |
|
|
Disaggregation of Revenue |
The following table represents disaggregated net product sales in the periods presented as follows (in thousands): | | | | | | | | | | | | | | Year Ended December 31, | | 2019 | | 2018 | | 2017 | Net product sales: | | | | | | EXPAREL / bupivacaine liposome injectable suspension | $ | 411,030 |
| | $ | 332,427 |
| | $ | 283,252 |
| iovera° | 7,896 |
| | — |
| | — |
| DepoCyt(e) | — |
| | — |
| | 1,090 |
| Total net product sales | $ | 418,926 |
| | $ | 332,427 |
| | $ | 284,342 |
|
|